Data / Drug companies / Clonidine
Clonidine: 9 companies and 16 products in the FDA NDC directory
Clonidine is listed in the FDA National Drug Code Directory by 9 companies, with 16 products in commercial distribution. 13 of the products (81.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are patch; patch, extended release; tablet, extended release, and the newest product started marketing on February 10, 2024.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 9
- Products
- 16
- Generic (ANDA) products
- 13 (81.2%)
- Application numbers
- 6
- Routes
- Transdermal, Oral, Epidural
- Brand names
- Nexiclon XR
- openFDA record search
- api.fda.gov
Companies that list clonidine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Actavis Pharma, Inc. | 3 | patch | Generic drugs (ANDA) | May 6, 2014 |
| Dr. Reddy's Laboratories Inc. | 3 | patch, extended release | Generic drugs (ANDA) | February 10, 2024 |
| Mylan Pharmaceuticals Inc. | 3 | patch | Generic drugs (ANDA) | March 4, 2013 |
| XGen Pharmaceuticals DJB, Inc. | 2 | injection, solution | Generic drugs (ANDA) | October 29, 2013 |
| Ingenus Pharmaceuticals, LLC | 1 | tablet, extended release | Generic drugs (ANDA) | March 5, 2019 |
| Mayne Pharma Inc. | 1 | patch, extended release | Generic drugs (ANDA) | August 3, 2016 |
| Palmetto Pharmaceuticals Inc. | 1 | tablet, extended release | Authorized generics (NDA) | March 1, 2022 |
| Rosemont Pharmaceuticals LLC | 1 | tablet, extended release | New drug applications (NDA) | March 1, 2022 |
| TruPharma, LLC | 1 | tablet, extended release | Authorized generics (NDA) | January 11, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Patch | 6 | 37.5% |
| Patch, extended release | 4 | 25% |
| Tablet, extended release | 4 | 25% |
| Injection, solution | 2 | 12.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 13 | 81.2% |
| Authorized generics (NDA) | 2 | 12.5% |
| New drug applications (NDA) | 1 | 6.2% |
Pharmacologic classes
| Class | Products |
|---|---|
| Central alpha-2 Adrenergic Agonist | 16 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.